Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone Intermediate

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism And Disposition

• Publication date

  2013-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.113.051151PMID 23404373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interaction of Lapatinib with Cytochrome P450 3A5

  2012influential reference
• High-Resolution Mass Spectrometry Elucidates Metabonate (False Metabolite) Formation from Alkylamine Drugs during In Vitro Metabolite Profiling

  2012cited by this paper
• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  2012influential reference
• Metabolic‐intermediate complex formation with cytochrome P450: Theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate

  2012cited by this paper
• Lapatinib‐Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes

  2012cited by this paper
• Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

  2012influential reference
• An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

  2011cited by this paper
• Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib

  2011influential reference
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cited by this paper
• Lapatinib-induced hepatitis: a case report.

  2011cited by this paper
• Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

  2010cited by this paper
• Sequential Metabolism of Secondary Alkyl Amines to Metabolic-Intermediate Complexes: Opposing Roles for the Secondary Hydroxylamine and Primary Amine Metabolites of Desipramine, (S)-Fluoxetine, and N-Desmethyldiltiazem

  2010influential reference
• In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran

  2009cited by this paper
• The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

  2009cited by this paper
• Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

  2008cited by this paper
• Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

  2008cited by this paper
• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  2005cited by this paper
• Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines

  2003cited by this paper
• Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem

  2000cited by this paper
• Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites.

  1996cited by this paper
• Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver.

  1992cited by this paper
• Interaction of constitutive and phenobarbital-induced cytochrome P-450 isozymes during the sequential oxidation of benzphetamine. Explanation for the difference in benzphetamine-induced hydrogen peroxide production and 455-nm complex formation in microsomes from untreated and phenobarbital-treated r

  1983cited by this paper
• Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans.

  1982cited by this paper
• Cytochrome P-455-nm complex formation in the metabolism of phenylalkylamines. VI. Structure--activity relationships in metabolic intermediary complex formation with a series of alpha-substituted 2-phenylethylamines and corresponding N-hydroxylamines.

  1982influential reference
• The non- and postenzymatic chemistry of N-oxygenated molecules.

  1982cited by this paper
• Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450.

  1981cited by this paper
• Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450.

  1981cited by this paper
• Cytochrome P-455 complex formation in the metabolism of phenylalkylamines--IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine.

  1979cited by this paper
• Formation of complexes between microsomal cytochrome P-450-Fe(II) and nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes in situ.

  1978cited by this paper
• Nitrosoalkanes as Fe(II) ligands in the hemoglobin and myoglobin complexes formed from nitroalkanes in reducing conditions.

  1977cited by this paper
• Nitrosoalkanes as new ligands of iron(II) porphyrins and hemoproteins.

  1977cited by this paper
• On the formation of cytochrome P-450 product complexes during the metabolism of phenylalkylamines.

  1976cited by this paper
• The formation of cytochrome P-450-metabolic intermediate complexes in microsomal fractions from extrahepatic tissues of the rabbit.

  1976cited by this paper
• The nature of the "455 nm absorbing complex" formed during the cytochrome P450 dependent oxidative metabolism of amphetamine.

  1976influential reference
• Dimethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)--in vivo and in vitro effects of metabolism by rat liver microsomes--formation of an oxygenated complex.

  1972cited by this paper
• Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms.

  1971cited by this paper
• Metabolic Oxidation of Aliphatic Basic Nitrogen Atoms and their α-Carbon Atoms

  1971cited by this paper
• Oxidations By Ferricyanide

  1958cited by this paper

• CYP3A4‐Mediated Metabolism and Drug–Drug Interaction Potential of Abemaciclib and Letrozole In Vitro

  2026cites this paper
• Electrochemistry and Antioxidant Activities of Substituted Furanyl Nitrone: The Role of the Nitro Group

  2025cites this paper
• Elucidating Molecular Mechanisms of Drug-Induced Hepatotoxicity of Lapatinib.

  2025cites this paper
• Analog of antiviral drug Triazavirin (Riamilovir) labeled with stable isotopes 13C and 15N. Synthesis and NMR characteristics

  2024cites this paper
• Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy

  2024influential citation
• What impact does tautomerism have on drug discovery and development?

  2024cites this paper
• The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.

  2023cites this paper
• The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib.

  2023cites this paper
• On the inhibition of cytochrome P450 3A4 by structurally diversified flavonoids

  2021cites this paper
• Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.

  2021cites this paper
• Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms

  2021cites this paper
• Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate.

  2021cites this paper
• Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity

  2020cites this paper
• Cytochrome P450 Inhibition

  2020cites this paper
• Intriguing generative metabolism discovery of reactive metabolite nitroso of lapatinib and relevant structural modification

  2020cites this paper
• Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants

  2020cites this paper
• The need for mathematical modelling of spatial drug distribution within the brain

  2019cites this paper
• Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor

  2019cites this paper
• Discovery of 2,4-diamino-5-cyanopyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions.

  2019cites this paper
• Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

  2019cites this paper
• Theoretical study on the mechanism of N- and α-carbon oxidation of lapatinib catalyzed by cytochrome P450 monooxygenase

  2019cites this paper
• Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation

  2019cites this paper
• Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.

  2018cites this paper
• Non-Dissociative Sequential Metabolism of Enoxacin to a Metabolic Intermediate Complex with Cytochrome P450 1A2

  2017cites this paper
• Cytochrome P 450 3 A 4 and CYP 3 A 5-Catalyzed Bioactivation of Lapatinib

  2016influential citation
• Emerging Novel Enzyme Pathways in Drug Metabolism Prevalence of Non – Cytochrome P 450 – Mediated Metabolism in Food and Drug Administration – Approved Oral and Intravenous Drugs : 2006 – 2015 s

  2016cites this paper
• OxaD: A Versatile Indolic Nitrone Synthase from the Marine-Derived Fungus Penicillium oxalicum F30.

  2016cites this paper
• Prevalence of Non–Cytochrome P450–Mediated Metabolism in Food and Drug Administration–Approved Oral and Intravenous Drugs: 2006–2015

  2016cites this paper
• Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents

  2016influential citation
• A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?

  2016cites this paper
• Iridium(III) Mediated Reductive Transformation of Closed-Shell Azo-Oxime to Open-Shell Azo-Imine Radical Anion: Molecular and Electronic Structure, Electron Transfer, and Optoelectronic Properties.

  2016cites this paper
• Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

  2016influential citation
• Effect of Natural Polyphenols on CYP Metabolism: Implications for Diseases.

  2015cites this paper
• Pharmacokinetic Interaction Study Combining Lapatinib with Vorinostat in Rats

  2015cites this paper
• Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib

  2015influential citation
• Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor–Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells

  2014cites this paper
• Drug Metabolism in Early Stage Drug Discovery and Drug Development

  2014cites this paper
• Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems

  2013cites this paper
• Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time- Dependent Inhibitor Systems s

  2013cites this paper
• Prediction of in vivo metabolite disposition and complex metabolite-dependent drug-drug interactions

  2013cites this paper
• Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems s

  2013cites this paper
• DMD054817 162..171

  2013cites this paper